Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents)
  4. Volume 25, Issue 1
  5. Article
Volume 25, Issue 1
  • ISSN: 1871-5206
  • E-ISSN: 1875-5992

Abstract

Aim

Novel MRP modulators are needed to combat MRP-mediated multidrug resistance (MDR) in cancer cells.

Background

Anticancer drug resistance is the main problem in cancer therapy. Causative multidrug efflux pumps are attractive target structures for the development of inhibitors of their activity.

Objective

We synthesized novel cage dimeric 1,4-dihydropyridines to evaluate them as MRP modulators in cancer cells targeting MRP1, MRP2, and MRP4.

Methods

Cage compounds were synthesized by solution dimerization of monomeric 1,4-dihydropyridines and a final functionalization reaction. The MRP modulation was determined in cellular efflux assays by the use of the flow cytometry technique as well as cellular fluorescent measurements with each fluorescent substrate of the efflux pumps.

Results

Difluoro phenyl and methoxy or dimethoxy benzyl substitutions were most favourable for the MRP1 and MRP2 inhibition, whereas monofluor phenyl and dimethoxy benzyl substitutions were most favourable for the MRP4 inhibition.

Conclusion

Effective inhibitors were identified that were demonstrated to restore the respective cancer cell line sensitivity for the anticancer drug as a proof-of-concept that encourages further preclinical studies.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/acamc/10.2174/0118715206331206240828111126
2025-01-01
2025-01-10

  • From This Site

    /content/journals/acamc/10.2174/0118715206331206240828111126
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Cancer.Available from: https://www.who.int/news-room/fact-sheets/detail/cancer 2024
  2. YanL. RosenN. ArteagaC. Targeted cancer therapies.Chin. J. Cancer20113011410.5732/cjc.010.1055321192839
     [Google Scholar]
  3. SarkarN. SinghA. KumarP. KaushikM. Protein kinases: Role of their dysregulation in carcinogenesis, identification and inhibition.Drug Res. (Stuttg.)202373418919910.1055/a‑1989‑185636822216
     [Google Scholar]
  4. LiJ. GongC. ZhouH. LiuJ. XiaX. HaW. JiangY. LiuQ. XiongH. Kinase inhibitors and kinase-targeted cancer therapies: recent advances and future perspectives.Int. J. Mol. Sci.20242510548910.3390/ijms2510548938791529
     [Google Scholar]
  5. Protein kinase inhibitors.2024Available from: https://brimr.org/protein-kinase-inhibitors/
  6. SinghaM. PuL. SrivastavaG. NiX. StanfieldB.A. UcheI.K. RiderP.J.F. KousoulasK.G. RamanujamJ. BrylinskiM. Unlocking the potential of kinase targets in cancer: Insights from canceromicsnet, an ai-driven approach to drug response prediction in cancer.Cancers (Basel)20231516405010.3390/cancers1516405037627077
     [Google Scholar]
  7. KannaiyanR. MahadevanD. A comprehensive review of protein kinase inhibitors for cancer therapy.Expert Rev. Anticancer Ther.201818121249127010.1080/14737140.2018.152768830259761
     [Google Scholar]
  8. ZahaviD. WeinerL. Monoclonal antibodies in cancer therapy.Antibodies (Basel)2020933410.3390/antib903003432698317
     [Google Scholar]
  9. HernandezI. BottS.W. PatelA.S. WolfC.G. HospodarA.R. SampathkumarS. ShrankW.H. Pricing of monoclonal antibody therapies: Higher if used for cancer?Am. J. Manag. Care201824210911229461857
     [Google Scholar]
  10. LinY.F. LiuJ.J. ChangY.J. YuC.S. YiW. LaneH.Y. LuC.H. Predicting anticancer drug resistance mediated by mutations.Pharmaceuticals (Basel)202215213610.3390/ph1502013635215249
     [Google Scholar]
  11. CatalanoA. IacopettaD. CeramellaJ. ScumaciD. GiuzioF. SaturninoC. AquaroS. RosanoC. SinicropiM.S. Multidrug resistance (MDR): A widespread phenomenon in pharmacological therapies.Molecules202227361610.3390/molecules2703061635163878
     [Google Scholar]
  12. DuanC. YuM. XuJ. LiB.Y. ZhaoY. KankalaR.K. Overcoming cancer Multi-drug Resistance (MDR): Reasons, mechanisms, nanotherapeutic solutions, and challenges.Biomed. Pharmacother.202316211464310.1016/j.biopha.2023.11464337031496
     [Google Scholar]
  13. KrchniakovaM. SkodaJ. NeradilJ. ChlapekP. VeselskaR. Repurposing tyrosine kinase inhibitors to overcome multidrug resistance in cancer: a focus on transporters and lysosomal sequestration.Int. J. Mol. Sci.2020219315710.3390/ijms2109315732365759
     [Google Scholar]
  14. WuC.P. HsiehC.H. WuY.S. The emergence of drug transporter-mediated multidrug resistance to cancer chemotherapy.Mol. Pharm.2011861996201110.1021/mp200261n21770407
     [Google Scholar]
  15. UghachukwuP.O. UnekweP.C. Efflux pump-mediated resistance in chemotherapy.Ann. Med. Health Sci. Res.20122219119810.4103/2141‑9248.10567123439914
     [Google Scholar]
  16. HilgerothA. HemmerM. CoburgerC. The impact of the induction of multidrug resistance transporters in therapies by used drugs: recent studies.Mini Rev. Med. Chem.201212111127113410.2174/13895571280276213022512559
     [Google Scholar]
  17. ZhangY.K. WangY.J. GuptaP. ChenZ.S. Multidrug Resistance Proteins (MRPs) and cancer therapy.AAPS J.201517480281210.1208/s12248‑015‑9757‑125840885
     [Google Scholar]
  18. YamadaA. IshikawaT. OtaI. KimuraM. ShimizuD. TanabeM. ChishimaT. SasakiT. IchikawaY. MoritaS. YoshiuraK. TakabeK. EndoI. High expression of ATP-binding cassette transporter ABCC1 in breast tumors is associated with aggressive subtypes and low disease-free survival.Breast Cancer Res. Treat.2013137377378210.1007/s10549‑012‑2398‑523288347
     [Google Scholar]
  19. YoungL.C. CamplingB.G. ColeS.P. DeeleyR.G. GerlachJ.H. Multidrug resistance proteins MRP3, MRP1, and MRP2 in lung cancer: correlation of protein levels with drug response and messenger RNA levels.Clin. Cancer Res.2001761798180411410522
     [Google Scholar]
  20. HlavataI. Mohelnikova-DuchonovaB. VaclavikovaR. LiskaV. PituleP. NovakP. BruhaJ. VycitalO. HolubecL. TreskaV. VodickaP. SoucekP. The role of ABC transporters in progression and clinical outcome of colorectal cancer.Mutagenesis201227218719610.1093/mutage/ger07522294766
     [Google Scholar]
  21. DriscollL.O´. WalshN. LarkinA. BallotJ. OoiW.S. GulloG. ConnorR.O´. ClynesM. CrownJ. KennedyS. MDR1/P-glycoprotein and MRP-1 drug efflux pumps in pancreatic carcinoma.Anticancer Res.2007274B21152120
     [Google Scholar]
  22. WalshN. LarkinA. KennedyS. ConnollyL. BallotJ. OoiW. GulloG. CrownJ. ClynesM. O’DriscollL. Expression of multidrug resistance markers ABCB1 (MDR-1/P-gp) and ABCC1 (MRP-1) in renal cell carcinoma.BMC Urol.200991610.1186/1471‑2490‑9‑619552816
     [Google Scholar]
  23. LiY.F. JiH.H. ZhangZ.L. ZhangT.T. GanW. ZhangS.F. Targeting MRP4 expression by anti-androgen treatment reverses MRP4-mediated docetaxel resistance in castration-resistant prostate cancer.Oncol. Lett.20171421748175610.3892/ol.2017.635728789405
     [Google Scholar]
  24. SavarajN. WuC. WangpaichitrM. KuoM. LampidisT. RoblesC. FurstA. FeunL. Overexpression of mutated MRP4 in cisplatin resistant small cell lung cancer cell line: Collateral sensitivity to azidothymidine.Int. J. Oncol.200323117317910.3892/ijo.23.1.17312792791
     [Google Scholar]
  25. ZhangY.H. WuQ. XiaoX.Y. LiD.W. WangX.P. Silencing MRP4 by small interfering RNA reverses acquired DDP resistance of gastric cancer cell.Cancer Lett.20102911768210.1016/j.canlet.2009.10.00319883972
     [Google Scholar]
  26. Oprea-LagerD.E. BijnsdorpI.V. Van MoorselaarR.J. Van den EertweghA.J. HoekstraO.S. GeldofA.A. ABCC4 Decreases docetaxel and not cabazitaxel efficacy in prostate cancer cells in vitro. Anticancer Res.201333238739123393328
     [Google Scholar]
  27. RobeyR.W. PluchinoK.M. HallM.D. FojoA.T. BatesS.E. GottesmanM.M. Revisiting the role of ABC transporters in multidrug-resistant cancer.Nat. Rev. Cancer201818745246410.1038/s41568‑018‑0005‑829643473
     [Google Scholar]
  28. GottesmanM.M. FojoT. BatesS.E. Multidrug resistance in cancer: Role of ATP–dependent transporters.Nat. Rev. Cancer200221485810.1038/nrc70611902585
     [Google Scholar]
  29. RottenbergS. JaspersJ.E. KersbergenA. van der BurgE. NygrenA.O.H. ZanderS.A.L. DerksenP.W.B. de BruinM. ZevenhovenJ. LauA. BoulterR. CranstonA. O’ConnorM.J. MartinN.M.B. BorstP. JonkersJ. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs.Proc. Natl. Acad. Sci. USA200810544170791708410.1073/pnas.080609210518971340
     [Google Scholar]
  30. PajicM. IyerJ.K. KersbergenA. Van der BurgE. NygrenA.O.H. JonkersJ. BorstP. RottenbergS. Moderate increase in Mdr1a/1b expression causes in vivo resistance to doxorubicin in a mouse model for hereditary breast cancer.Cancer Res.200969166396640410.1158/0008‑5472.CAN‑09‑004119654309
     [Google Scholar]
  31. YuX. WengZ. ZhaoZ. XuJ. QiZ. LiuJ. Assembly of protein cages for drug delivery.Pharmaceutics20221412260910.3390/pharmaceutics1412260936559102
     [Google Scholar]
  32. TapiaL. AlfonsoI. SolàJ. Molecular cages for biological applications.Org. Biomol. Chem.202119449527954010.1039/D1OB01737C34668919
     [Google Scholar]
  33. Ellis-DaviesG.C.R. Caged compounds: Photorelease technology for control of cellular chemistry and physiology.Nat. Methods20074861962810.1038/nmeth107217664946
     [Google Scholar]
  34. KreutzerD. DöringH. WernerP. RitterC.A. HilgerothA. Novel symmetrical cage compounds as inhibitors of the symmetrical mrp4-efflux pump for anticancer therapy.Int. J. Mol. Sci.202122509810.3390/ijms2210509834065900
     [Google Scholar]
  35. PoźniakB. PawlakA. Obmińska-MrukowiczB. Flow cytometric assessment of P-glycoprotein and multidrug resistance-associated protein activity and expression in canine lymphoma.In vivo201529114915325600546
     [Google Scholar]
  36. EvaA. RobbinsK.C. AndersenP.R. SrinivasanA. TronickS.R. ReddyE.P. EllmoreN.W. GalenA.T. LautenbergerJ.A. PapasT.S. WestinE.H. Wong-StaalF. GalloR.C. AaronsonS.A. Cellular genes analogous to retroviral onc genes are transcribed in human tumour cells.Nature1982295584511611910.1038/295116a06173755
     [Google Scholar]
  37. RiusM. NiesA.T. Hummel-EisenbeisJ. JedlitschkyG. KepplerD. Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane.Hepatology200338237438410.1053/jhep.2003.50331
     [Google Scholar]
  38. KimH.S. MinY.D. ChoiC.H. Double-edged sword of chemosensitizer: Increase of multidrug resistance protein (MRP) in leukemic cells by an MRP inhibitor probenecid.Biochem. Biophys. Res. Commun.20012831647110.1006/bbrc.2001.474611322768
     [Google Scholar]
  39. GollapudiS. KimC.H. TranB.N. SanghaS. GuptaS. Probenecid reverses multidrug resistance in multidrug resistance-associated protein-overexpressing HL60/AR and H69/AR cells but not in P-glycoprotein-overexpressing HL60/Tax and P388/ADR cells.Cancer Chemother. Pharmacol.199740215015810.1007/s0028000506409182837
     [Google Scholar]
  40. IsomuraS. AnzaiM. KobayashiC. OkunoY. MiyamotoK. UchiyamaM. SatoY. Chennat‐type synthesis of 1,4‐dihydropyridine derivatives in water: Role of a hydrogen‐bonding network.ChemistrySelect2020562075207710.1002/slct.201904144
     [Google Scholar]
  41. DeanS.W. LaneM. RuddockS.P. MartinC.N. KirklandD.J. LoprienoN. Development of assays for the detection of photomutagenity of chemicals during exposure to UV light.Mutagenesis1991633534110.1093/mutage/6.5.3351795636
     [Google Scholar]
  42. WangC. LuZ. Intermolecular [2 + 2] cycloaddition of 1,4-dihydropyridines with olefins via energy transfer.Org. Lett.201719215888589110.1021/acs.orglett.7b0288129048912
     [Google Scholar]
  43. HollensteinK. DawsonR.J.P. LocherK.P. Structure and mechanism of ABC transporter proteins.Curr. Opin. Struct. Biol.200717441241810.1016/j.sbi.2007.07.00317723295
     [Google Scholar]
  44. HaimeurA. ConseilG. DeeleyR. ColeS. The MRP-related and BCRP/ABCG2 multidrug resistance proteins: Biology, substrate specificity and regulation.Curr. Drug Metab.200451215310.2174/138920004348919914965249
     [Google Scholar]
  45. ChenZ.S. LeeK. KruhG.D. Transport of cyclic nucleotides and estradiol 17-beta-D-glucuronide by multidrug resistance protein 4. Resistance to 6-mercaptopurine and 6-thioguanine.J. Biol. Chem.200127636337473375410.1074/jbc.M10483320011447229
     [Google Scholar]
  46. Van AubelR.A.M.H. SmeetsP.H.E. PetersJ.G.P. BindelsR.J.M. RusselF.G.M. The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: Putative efflux pump for urinary cAMP and cGMP.J. Am. Soc. Nephrol.200213359560310.1681/ASN.V13359511856762
     [Google Scholar]
/content/journals/acamc/10.2174/0118715206331206240828111126
Loading
Evaluation of Novel Diaza Cage Compounds as MRP Modulators in Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents) 25, 63 (2025); https://doi.org/10.2174/0118715206331206240828111126
/content/journals/acamc/10.2174/0118715206331206240828111126
/content/journals/acamc/10.2174/0118715206331206240828111126
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): cellular efflux assays; Drug development; MDR modulating activity; MRP4; small-molecule inhibitors; substituent effects

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test